M.F. Alvisi

Predictors of Health-related Quality of Life and Adjustment to Prostate Cancer During Active Surveillance

Lara Bellardita, T. Rancati, M.F. Alvisi et al. · European Urology · 2013 · 89 citations

Quality Of Life, Urology, Cancer Epidemiology +9

Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer

Nicoletta Colombo, Federica Tomao, Pierluigi Benedetti Panici et al. · Gynecologic Oncology · 2022 · 67 citations · Full text

Phase Ii Trial, Medicine, Gynecology +9

High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial

Dora Buonfrate, Fabio Chesini, Davide Martini et al. · International Journal of Antimicrobial Agents · 2022 · 54 citations · Full text

Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts

Federica Guffanti, M.F. Alvisi, Alessia Anastasia et al. · British Journal of Cancer · 2021 · 34 citations · Full text

Oncology, Olaparib Response, Rad51 Foci +10

Eleven-year Management of Prostate Cancer Patients on Active Surveillance: What have We Learned?

C. Marenghi, M.F. Alvisi, F. Palorini et al. · Tumori Journal · 2017 · 25 citations · Full text